In an interview with Swissinfo, Simon Michel, CEO of Swiss medical device manufacturer, Ypsomed, explains why US tariffs represent only a limited challenge for his company and why he sees more growth from the success of GLP-1 drugs, blockbuster diabetes and obesity treatments such as Ozempic. Ypsomed is a global leader in drug delivery systems, technologies that allow patients to administer medicines themselves, such as self-injection pens for type 2 diabetes and obesity. The market for injection pens is expected to grow 7.9% annually from 2024 to 2030, reaching $74.1 billion (CHF 64.5 billion), according to consultancy MarketsandMarkets. Swiss bank UBS forecasts sales of GLP-1 drugs will climb to $126 billion by 2029, reflecting the surge in chronic diseases. Ypsomed has benefitted from this business environment. In May 2025, the company announced consolidated sales of CHF749 million for the fiscal year ending March 31, 2025 – a 38% increase compared to the previous year. In ...
